Nebenwirkungen · Temodal
Temodal 2.5 mg/ml powder for solution for infusion · Abschnitt 4.8 · PDF-Seite 27
HOS-089580 · Präparat HOS-083877
Tabulated list of adverse reactions Adverse reactions observed in clinical studies and reported from post-marketing use of TMZ are listed in Table 4. These reactions are classified according to System Organ Class and frequency. Frequency groupings are defined according to the following convention: Very common (≥ 1/10); Common (≥ 1/100 to < 1/10); Uncommon (≥ 1/1 000 to < 1/100); Rare (≥1/10 000 to <1/1 000); Very rare (<1/10 000); Not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-18T13:54:00Z · SHA-256 49a0026b6a071cadce495f46786dcd162d4d72e1fe7389385292e63aabdf9d0d · Passage dba6a32f57a5dfc22677b6dd22745acbb9b454e894cbeec14906314b4f6faac3 · Zeichen 678–1271 im Abschnitt